%0 Journal Article
%T The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated nonsmall cell lung cancer
%A Anthony M. Brade
%J SCIE-indexed Journal
%D 2017
%X While this quote is likely apocryphal and not, as is commonly attributed, a curse of Chinese origin (1), its ironic sentiment seems apt when one considers the rapidly shifting treatment landscape for patients with brain metastases. This is particularly true for non-small cell lung cancer, where systemic therapy is now frequently dictated by driver mutation-driven sub-categorization. The ¡°seismic¡± changes in management for these groups of patients are being driven by the collision of two ¡°tectonic¡± clinical forces: (I) development of molecularly-targeted, systemic therapies with clinically significant CNS activity; and (II) the shift towards tumour-targeted vs. whole brain radiotherapy (WBRT) [debated in (2,3)]. The resulting upheaval and emergence of a new ¡°treatment geography¡± in this clinical space has made for ¡°interesting times¡± indeed
%U http://tlcr.amegroups.com/article/view/17216/14110